Skip to main content
TRIVARX LTD logo

TRIVARX LTD — Investor Relations & Filings

Ticker · TRI ISIN · AU0000300196 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,274 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country AU Australia
Listing ASX TRI

About TRIVARX LTD

https://trivarx.com/

TrivarX Ltd is a digital health company focused on the development and commercialization of screening and diagnostic technologies for mental health conditions. The company's core offering is the Sleep Analysis Management and Screening (SAMAS) platform, an AI-driven solution designed to identify biomarkers associated with Major Depressive Disorder (MDD). By utilizing proprietary algorithms to analyze sleep architecture and physiological data, the platform provides a non-invasive method for assessing mental health status. TrivarX aims to integrate its technology into clinical workflows to assist healthcare providers in early detection and objective monitoring of depressive symptoms. The company's research and development efforts prioritize the validation of digital biomarkers to improve diagnostic accuracy and patient outcomes in the mental health sector.

Recent filings

Filing Released Lang Actions
CRO Engaged to Advance Stabl-Im Phase 1 Trial 2 pages 186.7KB
Regulatory Filings Classification · 12% confidence The document is an ASX announcement regarding the engagement of a contract research organisation for a clinical Phase 1 safety trial. It contains no financial statements, vote results, management changes, or investor presentation slides; rather, it’s a routine regulatory announcement of a corporate development. Thus it best fits the general regulatory filings category (RNS).
2026-05-21 English
March 2026 Quarterly Activities Report and Appendix 4C 8 pages 458.6KB
Regulatory Filings
2026-04-29 English
Dr Danielle Meyrick appointed as CEO 5 pages 300.9KB
Board/Management Information Classification · 85% confidence The document is an ASX announcement concerning the appointment of Dr Danielle Meyrick as the company’s new Chief Executive Officer, detailing her background, terms of employment, incentive awards and key agreement provisions. This is clearly a management change announcement, fitting the Board/Management Information category.
2026-04-28 English
Key management changes 3 pages 236.5KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 5 March 2026 from TrivarX Limited. It details key management changes including the departure of the Chief Medical Officer, enhanced director involvement, changes to the Company Secretary, and updates to director remuneration. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no indication of a report being attached or published. The content focuses exclusively on changes in senior management and board-related roles. Therefore, this document fits the category of Board/Management Information (MANG). The document length (7,565 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2026-03-04 English
Appendix 4D & Half-Year Financial Report to 31 December 2025 25 pages 1.1MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ASX APPENDIX 4D HALF-YEAR FINANCIAL REPORT TO 31 DECEMBER 2025' and contains detailed financial statements, directors' report, auditor's review report, and comprehensive financial data for the half-year period ending 31 December 2025. It includes consolidated statements of profit or loss, financial position, cash flows, and notes to the financial statements. The presence of an auditor's review report and detailed financial analysis confirms this is a half-year financial report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2026-02-23 English
December 2025 Quarterly Activities Report and Appendix 4C 9 pages 490.2KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 30 January 2026, titled 'Quarterly Activities Report' for the three-month period ended 31 December 2025. It details clinical trial results, intellectual property acquisition, a capital raising placement, a director resignation, and a financial overview including cash flow data. The content focuses on operational updates, clinical trial outcomes, strategic acquisitions, and financial cash flow for the quarter, which aligns with a quarterly report. The presence of substantive financial data (cash flow statement) and detailed operational and clinical progress confirms this is a comprehensive interim/quarterly report rather than a brief announcement or investor presentation. It is not an earnings release as it contains more detailed financial and operational information. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-01-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.